

Funds Raised to date: \$134M



**COLLABORATORS:**

Families of SMA  
Tufts University  
Warner Chilcott

**INSTITUTIONAL INVESTORS:**

Aisling Capital  
BioFund  
Bioveda Capital  
Boston Life Science Venture Corp  
Coller Capital  
DE Shaw  
GeneChem Therapeutics  
HBM BioVentures  
K/S Danish Bioventure  
Novartis Bioventures  
Omega Fund  
Phase4 Ventures  
POD Holding  
Wheatley Medtech Partners

**BOARD OF DIRECTORS:**

Walter Gilbert, Ph.D.  
*Chairman of the Board*

Stuart B. Levy, M.D.  
*Vice Chairman & CSO*

Thomas J. Bigger  
*President & CEO, Director*

Kenneth J. Novack  
*Director*

Dennis Purcell  
*Director*

Patricia Smith, M.D.  
*Director*

Otello Stampacchia, Ph.D.  
*Director*

Pieter Strijkert, Ph.D.  
*Director*

Anthony Y. Sun, M.D.  
*Director*

**OVERVIEW**


Paratek Pharmaceuticals, Inc. is a private biopharmaceuticals company headquartered in Boston, MA, that is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening infectious diseases. Paratek’s mission is to develop new antibiotic and anti-infective products that address the major worldwide problem of bacterial resistance and to pursue additional promising applications of the Company’s technology into other disease areas such as inflammation.

**PRODUCT RESEARCH AND DEVELOPMENT PROGRAMS**

Paratek has established two product development platforms to identify and develop multiple products for the treatment of infectious and other serious diseases:

- The Tetracycline (“TET”) Program is based on Paratek’s expertise in medicinal chemistry, from which the Company’s lead compound PTK 0796 is currently in Phase 3 clinical studies.
- The Multiple Adaptational Response (“MAR”) Program is based on novel discoveries in pathogen genomics.

**SUMMARY OF PRODUCT PIPELINE AND DEVELOPMENT STATUS**



**TETRACYCLINE PROGRAM**

When first introduced over 50 years ago, tetracyclines were used as first-line agents against a broad spectrum of bacteria. Worldwide, tetracyclines are still among the most commonly used anti-infective agents to combat bacterial infections. However, emergence of resistance has sharply curtailed their effectiveness as antibiotics, while newly discovered non-antibiotic uses are increasingly driving the use of tetracyclines. Given physicians’ familiarity with and acceptance of the tetracyclines such as minocycline and doxycycline, Paratek believes that its ability to create next generation classes of compounds derived from the tetracycline class will yield a diversity of novel, more effective and clinically useful products that may again be used as first line antibiotics and other disease modifying treatments for serious diseases.

**Antibiotics**

Paratek has developed new classes of antibiotics, derived from the tetracycline class, that are designed to inhibit susceptible and multi-drug-resistant bacteria. In animal and human studies these new antibiotics are well tolerated with desirable toxicity and safety profiles.

### **Leading Clinical Program: PTK 0796 for Hospital Infections**

Paratek has discovered a promising new class of antibiotics called the aminomethylcyclines (AMCs), derived from the tetracycline class. The leading AMC in clinical development is PTK 0796, an oral and IV once-daily antibiotic agent with activity against resistant and susceptible gram-positive, gram-negative, atypical and anaerobic bacteria, including multi-drug resistant bacteria, such as methicillin-resistant *Staphylococcus aureus* (MRSA). PTK 0796 is being developed as a first-line agent for empiric therapy primarily for serious infections, including those treated in the hospital and community, such as acute bacterial skin and skin structure infections (ABSSSIs) and moderate to severe community-acquired bacterial pneumonia (CABP). A Phase 2 cSSSI study was completed and presented at ICAAC in 2008, where oral and IV forms of PTK 0796 compared very favorably against Zyvox®. Phase 3 has been initiated.

### **Other Compounds**

Paratek has synthesized more than 2,500 novel tetracycline compounds. These new compounds offer product opportunity in multiple sclerosis, inflammatory bowel diseases (ulcerative colitis and Crohn's disease), acne and ischemia (stroke and AMI).

Outside of the anti-inflammatory area, selected Paratek compounds have been found to bind to RNA and affect splicing in a beneficial way in the devastating genetic disease spinal muscular atrophy (SMA) and other genetic splicing disorders.

Paratek's chemistry expertise and knowledge of the structure activity relationships of the molecules has enabled Paratek to engage in a targeted approach to identify new compounds that have commercial potential. Many of Paratek's new compounds are currently undergoing *in vitro* and *in vivo* testing to assess their use in antibacterial, anti-inflammatory and other therapeutic applications.

### **MAR PROGRAM**

In the MAR Program, Paratek is exploiting its discovery of the mar operon, a novel "master switch" that controls expression of over 80 genes in clinically important bacteria. When activated, the MAR system initiates a number of bacterial survival and defense mechanisms, including processes whereby bacteria establish infections and develop resistance to antibiotics. Paratek has synthesized a series of small organic molecules (MAR inhibitors) that target and inhibit MarA and related proteins. Paratek has shown that these MAR inhibitors prevent infection *in vivo*. MAR inhibitors can be envisioned as broad-spectrum agents that decrease bacterial virulence and prevent infection in many clinically relevant settings where patients are at high-risk of contracting bacterial infections, such as ventilator-associated pneumonia and urinary tract infections. MAR inhibitors may also be useful as adjunct therapy to improve the effectiveness of currently available antibiotics.

### **COMMERCIAL PARTNERSHIPS**

In July 2007, Paratek entered into an agreement with Warner-Chilcott for the development and commercialization of improved tetracycline-derived narrow-spectrum antibiotics for the treatment of acne and rosacea. Lead compounds with improved anti-inflammatory activity and potential for reduced side effects and intolerabilities compared to older tetracyclines were identified and are currently in Phase 1 clinical studies. Under its agreement with Warner-Chilcott, Paratek received an upfront payment and is eligible for further clinical development and regulatory approval milestone payments, and royalties for U.S. rights to the use of these compounds in acne and rosacea.

In December 2007, Paratek entered into a Collaborative Agreement with a leading Global Animal Health Company to develop novel and improved oral tetracycline-based compounds for the treatment of BRD and PRD infections in livestock. Under this agreement, Paratek assists in development efforts, but the Global Animal Health Company is responsible for funding and all development and commercialization of compounds that arise from the collaboration. Paratek received an initial upfront payment, research support and will receive further milestones for progress in clinical development and with regulatory authorities and royalties on any product sales under this agreement. Lead and back-up compounds have been identified, and clinical studies are underway.

## **MANAGEMENT**

Thomas J. Bigger  
*President & Chief Executive Officer*

Stuart B. Levy, M.D.  
*Chief Scientific Officer*

Kathryn M. Boxmeyer  
*Vice President, Chief Financial Officer & Treasurer*

Beverly A. Armstrong, JD, MBA  
*Vice President, General Counsel & Chief Compliance Officer*

Gary J. Noel, M.D.  
*Vice President and Chief Medical Officer*

S. Ken Tanaka, Ph.D.  
*Vice President, Research and Development*

Sean M. Johnston  
*Vice President, Operations*

Dennis Molnar  
*Vice President, Corporate Development*

---

## **CONTACT DETAILS**

75 Kneeland Street  
Boston, MA 02111  
Tel: 617/275-0040  
Fax: 617/275-0039

[www.paratekpharm.com](http://www.paratekpharm.com)

Investor Relations  
[ir@paratekpharm.com](mailto:ir@paratekpharm.com)

Business Development  
[bd@paratekpharm.com](mailto:bd@paratekpharm.com)

Human Resources  
[hr@paratekpharm.com](mailto:hr@paratekpharm.com)